Investigating drug resistance in HIV patients on Dolutegravir treatment
HIV-1 subtype, specific drug resistance in patients failing Dolutegravir-based 1st, 2nd or 3rd line regimens: the International epidemiological Databases to Evaluate AIDS (IeDEA)
This study is looking at how some people with HIV-1 might not respond to the medication Dolutegravir, and it aims to find out why that happens so we can help improve treatment for both adults and teens living with HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Universitat Bern NIH-funded |
| Lab location | 1 site (Bern, SWITZERLAND) |
| Project ID | NIH-10898745 on NIH RePORTER |
What this research studies
This research focuses on understanding how HIV-1 can develop resistance to Dolutegravir, a key medication used in treating HIV. By analyzing data from various international cohorts, the study aims to identify patterns of drug resistance mutations in patients who are not responding to their treatment. It will also explore the risk factors that contribute to treatment failure in both adults and adolescents. The findings could help improve treatment strategies and patient outcomes in the fight against HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults and adolescents who are currently on Dolutegravir-based antiretroviral therapy and experiencing treatment failure.
Not a fit: Patients who are not on Dolutegravir or those who have not experienced treatment failure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better treatment options for HIV patients experiencing drug resistance.
How similar studies have performed: Previous research has shown success in understanding drug resistance patterns in HIV, making this approach both relevant and necessary.
Where this research is happening
Bern, SWITZERLAND
- Universitat Bern — Bern, Switzerland (Active)
Researchers
- Principal investigator: Egger, Matthias — Universitat Bern
- Study coordinator: Egger, Matthias
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.